Electra Therapeutics Raises $350 Million in Upsized IPO, Then Slips in Nasdaq Debut

What happened

Electra Therapeutics, a South San Francisco-based biotech developing precision medicines for immune-mediated diseases and cancer, began trading on the Nasdaq Global Select Market on Sept. 18 under the ticker ETRA. The company priced an upsized initial public offering late on Sept. 17, raising about $350 million in gross proceeds.

According to IPOScoop, the stock opened flat at its $15 offering price and closed its first day at $13.25, down about 11.7%.

Offering details

• Shares: 23,333,334 shares of common stock, all sold by Electra, up from 21.67 million shares in the preliminary prospectus.
• Price: $15.00 per share, the midpoint of the $14 to $16 range.
• Gross proceeds: About $350 million before underwriting discounts and expenses.
• Underwriter option: Up to 3.5 million additional shares within 30 days.
• Banks: Jefferies, TD Cowen, Evercore ISI and Cantor were joint book-running managers.
• Closing: Expected Sept. 21, subject to customary conditions.

IPOScoop put Electra’s market capitalization at about $941 million at the IPO price and listed OrbiMed and Westlake Biopartners among its principal stockholders. The company reported a net loss of $85.53 million and no revenue for the 12 months ended June 30, 2026.

Company details

Electra describes itself as a late clinical-stage company whose approach targets SIRP (signal regulatory protein) cell surface receptors. Its programs include:

• Ipsoprubart (ELA026): A pan-SIRP monoclonal antibody in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory syndrome, and in a Phase 1 trial for relapsed or refractory T-cell and natural killer cell malignancies.
• ELA822: A clinical-stage SIRP-gamma-specific antibody for chronic T cell-mediated immune and inflammatory diseases.

According to IPOScoop, Electra plans to use about $220 million of net proceeds to fund a global Phase 2/3 trial of ipsoprubart in sHLH. The Phase 1 study in T-cell and NK-cell malignancies is expected to report initial data in the second half of 2027.

Why it matters for the sector

Electra is one of the larger biotech IPOs of 2026, a year in which the listing window reopened after several slow years. A raise of this size gives the company funding for a registrational program, which is the kind of late-stage story that crossover and public investors have favored.

The first-day decline, however, shows that size alone does not guarantee aftermarket strength. Pricing at the midpoint rather than above the range, combined with a drop on day one, suggests investors were selective about valuation even as demand was sufficient to upsize the share count.

Secondary HLH is a rare and serious condition with limited approved treatment options, and companies developing therapies for it can benefit from orphan drug incentives. A registrational program also gives Electra a nearer-term regulatory catalyst than many early-stage IPO candidates.

Aftermarket performance of fall listings will influence how other companies in the IPO queue price their deals. Bankers and investors tend to compare recent debuts when setting ranges for upcoming offerings.

What to watch

• Closing of the IPO and any exercise of the underwriters’ option.
• Enrollment progress in the ipsoprubart registrational program in sHLH.
• Initial Phase 1 data in T-cell and NK-cell malignancies, expected in the second half of 2027.
• Trading of other recent biotech IPOs as additional companies seek to price this fall.

This article is for information only and is not investment advice.

Sources: Electra Therapeutics press release (via BioSpace), IPOScoop

The IPO Process, From Filing to First Trade

An initial public offering follows a well-worn sequence in the United States. Knowing the steps helps explain terms such as “upsized” and “midpoint” that appear in coverage of debuts like Electra’s.

1. Registration statement. The company files a registration statement with the Securities and Exchange Commission, describing its business, risks, finances and plans for the money.
2. Price range. Once the regulator’s review is far enough along, the company sets an expected price range and number of shares.
3. Roadshow. Management presents to institutional investors, and underwriters collect indications of interest.
4. Pricing. The night before trading begins, the company and its banks set the final price and share count. Strong demand can lead to an upsized deal, a price above the range or both.
5. First trade. Shares begin trading the next morning. The opening price reflects supply and demand, not the offering price.
6. Closing. A few days later, the company receives its proceeds and the shares are formally delivered.

What Happens After Day One

A first-day move gets attention, but several later milestones tend to matter more for a newly public biotech:

• Analyst coverage. Research from the underwriting banks typically begins after a quiet period of several weeks.
• Lock-up expiration. Existing holders, including insiders and venture investors, usually agree not to sell for a set period, commonly around 180 days. When that period ends, additional supply can affect trading.
• First earnings report. The company’s first quarterly filing as a public company updates its cash position and spending.
• Clinical milestones. For development-stage biotechs, trial enrollment and data readouts drive valuation far more than the IPO price itself.

A Primer on Secondary HLH

Hemophagocytic lymphohistiocytosis is a syndrome in which the immune system becomes dangerously overactivated. Immune cells release large amounts of inflammatory signals and can damage organs, including the liver, bone marrow and brain. The “secondary” form is triggered by another condition, such as a severe infection, cancer or autoimmune disease, rather than by an inherited genetic defect.

Because the syndrome progresses quickly and can be life-threatening, it is usually managed in hospitals by specialists. Current approaches aim to calm the immune response and treat the underlying trigger. The need for more targeted options is why programs in this setting draw interest.

Questions Readers Ask

What is a registrational trial?

A study designed to generate the evidence needed to support an application for regulatory approval. A Phase 2/3 design combines a dose-confirming stage with a larger stage intended to establish efficacy.

Does a first-day decline mean an IPO failed?

Not necessarily. The company still raised the capital it sought. A decline does affect investor sentiment and may influence how other companies price their own deals.

Who are crossover investors?

Funds that invest in private companies shortly before an IPO and continue holding shares after listing, bridging private and public markets.

What is a pan-SIRP antibody?

An antibody designed to bind several members of the SIRP receptor family rather than just one, which can broaden its effect on immune signaling. Patients should discuss any condition and treatment with their own physicians.